Dr. Seftel and colleagues provided an update in the August 2015 issue of Mayo Clinic Proceedings for clinicians treating hypogonadal men, where they looked at the most recent Endocrine Society guidelines from 2010 and note where changes could be made or where evidence neither supports or denies efficacy and safety of testosterone therapy. Notably, patients with frailty and metabolic syndrome are two instances where changes are recommended. No Level 1 evidence was found to suggest that TRT is associated with CV disease.
View Dr. Seftel's presentation of the update.
Dr. Seftel is distinguished as the only urologist and sexual health expert included on the American Heart Association’s writing panel that recently released the groundbreaking scientific statement “Sexual Activity and Cardiovascular Disease.” The 2012 statement provides recommendations for when sexual activity is safe for heart patients and encourages physicians to take the time to discuss the matter. Decreased sexual activity and function are common in patients with cardiovascular disease and often leads to depression and anxiety. The statement was approved by the American Heart Association’s Science Advisory Committee and endorsed by the American Urological Association, the Society for Thoracic Surgeons, the International Society for Sexual Medicine and many other professional societies.
To read more, click here
Dr. Seftel recently took part in a Point-Counterpoint session at the American Urological Association 2013 Annual Meeting regarding identifying cardiovascular risk in patients with erectile dysfunction. In his presentation he explained why he believes it is important for urologists to screen male patients for cardiovascular disease:
Should the Urologist Perform Cardiac Disease Screening in the Management of the Erectile Dysfunction Patient?
Moderator: Francesco Montorsi, MD
Debater Pro: Allen D. Seftel, MD
Debater Con: Serge Carrier, MD
Dr. Seftel's recently published research also includes:
Retrospective analysis of the efficacy and safety of once-daily Tadalafil in patient subgroups: Men with mild vs moderate ED and aged <50 vs >50 years.
Seftel AD, Shinghal R, Kim ED, Samuels SM, Ni X, Burns PR.
Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.
Zhang X, Zang N, Wei Y, Yin J, Teng R, Seftel A, Disanto ME.
Am J Physiol Endocrinol Metab. 2012 Jan;302(2):E243-53. Epub 2011 Oct 25.
Blebbistain, a myosin II inhibitor, as a novel strategy to regulate detrusor contractility in a rat model of partial bladder outlet obstruction.
Zhang X, Seftel A, DiSanto ME.
PLoS One. 2011;6(10):e25958. Epub 2011 Oct 7.
Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes.
Miner M, Seftel AD, Nehra A, Ganz P, Kloner, RA, Montorsi P, Vlachopoulos C, Ramsey M, Sigman M, Tilkemeier P, Jackson, G
Am Heart J, 2012 Jul;164(1):21-8. Epub2012 Jun 7
The NERI Hypogonadism Screener: psychometric validation in male patients and controls.
Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, Miner MM, Shabsigh R. Clin Endocrinol
(Oxf). 2011 Feb;74(2):248-56. doi: 10.1111/j.1365-2265.2010.03925.x.
The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease.
Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, Carson CC, Cunningham GR, Ganz P, Goldstein I, Guay AT, Hackett G, Kloner RA, Kostis J, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel AD, Shabsigh R, Vlachopoulos C, Wu FC.
Mayo Clin Proc. 2012 Aug;87(8):766-78.
Coexisting lower urinary tract symptoms and erectile dysfunction: A systematic review of epidemiological data.
Seftel AD, de la Rosette J, Birt J, Porter V, Zarotsky V, Viktrup L.
Int J Clin Pract. 2012 Oct 22. doi: 10.1111/ijcp.12044.